A Reversal for Aralez Pharmaceuticals Inchares (NASDAQ:ARLZ) Is Near. The Stock Has Decrease in Shorts

June 18, 2018 - By Ash

The stock of Aralez Pharmaceuticals Inchares (NASDAQ:ARLZ) registered a decrease of 0.53% in short interest. ARLZ’s total short interest was 3.37 million shares in June as published by FINRA. Its down 0.53% from 3.38M shares, reported previously. With 355,900 shares average volume, it will take short sellers 10 days to cover their ARLZ’s short positions. The short interest to Aralez Pharmaceuticals Inchares’s float is 6.49%.

The stock decreased 1.76% or $0.0077 during the last trading session, reaching $0.4293. About 395,637 shares traded. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) has declined 72.77% since June 18, 2017 and is downtrending. It has underperformed by 85.34% the S&P500.

Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical firm in the United States and Canada. The company has market cap of $29.04 million. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It currently has negative earnings. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.

Another recent and important Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) news was published by Seekingalpha.com which published an article titled: “Update On Aralez Pharmaceuticals” on June 18, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: